BUSINESS, MARKETS & FINANCE
By Collin Eaton and Benoit Morenne
ExxonMobil and oil billionaire Harold Hamm are moving toward preliminary agreements to invest in Venezuela's oil fields, signaling renewed U.S. corporate interest in reviving the country's aging energy sector. Exxon could sign a memorandum of understanding with state-run PDVSA as soon as this month covering fields holding a combined 50 billion barrels, according to people familiar with the talks. Separately, Hamm's Continental Resources signed a preliminary deal at a Houston energy conference to explore an undeveloped field and hopes to reach a production-sharing agreement within weeks. The moves follow the Trump administration's push, including Secretary of State Marco Rubio, to steer roughly $100 billion of investment into Venezuela and redirect its crude to U.S. refineries. Rival Chevron already committed $7 billion this month to roughly double its Venezuelan output, though some companies remain wary of the country's history of nationalizing foreign assets.
Why It Matters: A wave of new U.S. investment could push Venezuelan output past its historic peak, reshaping crude supplies for Gulf Coast refiners while testing whether Caracas's legal overhaul holds up.
- Exxon may sign a memorandum of understanding with PDVSA as soon as this month for fields holding 50 billion barrels.
- Continental Resources, led by Harold Hamm, signed its own preliminary deal to explore a field in Anzoátegui state.
- Hamm says the investment wave could push Venezuelan production above its historic peak of 3 million barrels a day.
- Chevron separately committed $7 billion this month to roughly double its Venezuelan output to 600,000 barrels a day.
- Exxon CEO Darren Woods called Venezuela “uninvestable” in a January White House meeting before the country overhauled oil regulations.
- Venezuela has since lowered oil-production tax rates and revised its legal framework, Continental says.
- Trump officials including Secretary of State Marco Rubio are pushing roughly $100 billion in Venezuelan investment.
- Some large oil companies remain cautious, citing Venezuela's history of nationalizing private assets.
BUSINESS, MARKETS & FINANCE
By Alex Janin and Adrià Calatayud
Novo Nordisk, maker of Ozempic and Wegovy, is partnering with Anthropic to apply the AI company's science-focused Claude Science platform to drug discovery and software development. Novo is the latest big pharmaceutical name to chase AI-driven shortcuts to new medicines, following similar wagers by Eli Lilly, Merck and Roche. Executives from both companies frame the deal as a way to compress the years-long path from research to an approved product, though no AI-discovered drug has yet reached approval anywhere in the industry. Industry figures say AI's clearest gains so far come from automating routine work such as synthesizing research and identifying patients for clinical trials rather than making discoveries itself. Novo has separate AI partnerships this year with OpenAI and Amazon Web Services, and did not disclose specific financial terms for the Anthropic deal.
Why It Matters: Drugmakers are betting years of R&D spending on AI tools that have yet to produce a single approved medicine, a gap investors and patients should watch closely.
- Novo Nordisk will use Anthropic's Claude Science platform for drug discovery and internal software development.
- Novo joins Eli Lilly, Merck and Roche among drugmakers pursuing AI partnerships this year.
- No AI-discovered drug candidate has won regulatory approval anywhere in the industry so far.
- Novo CEO Mike Doustdar says AI can aid reasoning about human biology and drug mechanics beyond automating tasks.
- Consultant Bill Coyle says AI has proven useful for spotting rare-disease patients hidden in large health-record data sets.
- Novo separately struck AI partnerships this year with OpenAI and built an innovation hub with Amazon Web Services.
- Anthropic CEO Dario Amodei says the collaboration aims to shorten research timelines and improve treatment outcomes.
- Novo did not disclose financial terms or which specific drug programs the Anthropic partnership will target.
BUSINESS, MARKETS & FINANCE
By Ryan Felton
The House voted Tuesday by a lopsided, bipartisan margin to approve the AM Radio for Every Vehicle Act, dealing a setback to automakers that have been dropping AM tuners from new models. The bill, which now heads to a Senate version with 60 co-sponsors, would require the Transportation Department to mandate AM radio within a year if enacted, with enforcement authority lasting eight years. Broadcasters and former emergency officials argued the century-old band remains critical for public alerts when cell networks and power fail, a case echoed by National Association of Broadcasters chief Curtis LeGeyt. Automakers, including Tesla, Volvo and BMW, had phased out AM receivers partly because electric-vehicle motors can interfere with the signal; an industry-funded study put the cost of fixing that interference at $3.8 billion. Ford, which initially dropped AM radio, reversed course after CEO Jim Farley cited the technology's role in emergency alerts.
Why It Matters: Automakers now face an unwanted federal mandate and potentially billions in interference-mitigation costs just as they juggle tariffs, rising fuel prices and Chinese competition.
- The House passed the AM Radio for Every Vehicle Act on Tuesday with overwhelming bipartisan support.
- A companion Senate bill already has 60 co-sponsors and bipartisan backing.
- If enacted, the Transportation Department must issue an AM radio mandate within one year, enforceable for eight years.
- Tesla, Volvo and BMW are among automakers that dropped AM tuners from newer models.
- An industry-funded Center for Automotive Research study estimated fixing EV interference with AM signals would cost $3.8 billion.
- Ford reversed its decision to drop AM radio after CEO Jim Farley cited its emergency-alert role.
- More than 4,000 AM stations remain on air even as FM and other options have drawn listeners away.
- Broadcasting group chief Curtis LeGeyt calls AM radio a lifeline when cell networks and power both fail.
PRINT ONLY B3 · BUSINESS, MARKETS & FINANCE
Papa John’s Vows Improvements
By Heather Haddon
Papa John's CEO Todd Penegor told an investor event Wednesday that reversing the pizza chain's prolonged sales slump starts with improving pizza quality itself. U.S. same-store sales have declined for several consecutive quarters, and the company's stock has fallen 48% so far this year. Penegor said the chain is focused on rebuilding its reputation as a good value while also reviewing kitchen operations, including dough handling on speed-focused equipment, sauce sweetness, cheese melt and topping presentation. He acknowledged the turnaround is taking longer than he had hoped but said the company intends to review every part of the product.
Why It Matters: Investors watching a stock that has lost nearly half its value this year now have a concrete list of the product fixes management says must happen before sales recover.
- Papa John's CEO Todd Penegor said quality improvements must come before the sales turnaround can succeed.
- U.S. same-store sales have declined for several consecutive quarters.
- Papa John's stock has fallen 48% so far this year.
- Penegor said the turnaround is taking longer than he had hoped.
- The company is reviewing dough handling on crust-speed equipment, sauce sweetness, cheese melt and topping presentation.
- Penegor said the chain wants to rebuild its reputation as a good value for the money.
BUSINESS, MARKETS & FINANCE
By Liz Young
Reckitt Benckiser, maker of Mucinex and Lysol, said Wednesday it will invest about $400 million over four years to expand U.S. manufacturing and speed product development, building on a $200 million commitment made in 2024. Much of the money will roughly double investment in Reckitt's Wilson, N.C., plant, adding 234,000 square feet and making it the company's largest U.S. over-the-counter manufacturing site, capable of producing more than 80% of its Mucinex products domestically. Reckitt is also consolidating commercial and research operations onto one campus in Nutley, N.J., moving its Lysol-focused R&D team there from Montvale and building a new science-and-innovation center. Executives said the buildout is meant to help the company respond faster to shifting cold-and-flu seasons and reduce reliance on factories in Mexico and the U.K. North America supplied about 23% of Reckitt's core revenue in the first half of the year, compared with larger shares from Europe and emerging markets.
Why It Matters: Faster domestic production could mean Reckitt gets cold and flu medicines onto shelves before rivals when outbreak timing shifts, directly affecting availability for U.S. consumers each winter.
- Reckitt will invest about $400 million over four years, adding to a $200 million 2024 commitment.
- The Wilson, N.C., plant will grow by 234,000 square feet and become Reckitt's largest U.S. OTC manufacturing site.
- More than 80% of Reckitt's Mucinex products will eventually be made in the U.S. under the plan.
- Reckitt is moving Lysol-focused research and development to a new campus in Nutley, N.J., from Montvale.
- The company moved its North American headquarters to Nutley from Parsippany in January.
- North America generated about 23% of Reckitt's core revenue in the first half of the year.
- A University of Tennessee supply-chain professor says regional plants respond faster to localized demand swings than single overseas bases.
PRINT ONLY B3 · BUSINESS, MARKETS & FINANCE
J.B. Hunt Expects Lower Profit On Higher Driver-Related Costs
By Esther Fung
J.B. Hunt Transport Services CFO Brad Delco said Wednesday the trucking company expects third-quarter earnings to decline roughly 5% to 10% from the second quarter because of rising driver-related costs, fuel prices and insurance claims. Delco, speaking at a Morgan Stanley investor conference, said recruiting, training and sign-on bonus costs alone will add about $25 million in the third quarter compared with the second. J.B. Hunt shares fell 13% to $236.73 Wednesday following the disclosure. Delco framed the added driver spending as a positive sign of the company's growth focus, while also citing a roughly $10 million fuel-cost headwind as diesel prices reached $6.29 a gallon, up 68% from a year earlier. He linked the driver shortage partly to federal restrictions on which immigrants can obtain commercial driving eligibility.
Why It Matters: Shippers and investors should expect higher freight costs to persist as trucking companies pass along driver recruitment and fuel expenses building since spring.
- J.B. Hunt expects third-quarter earnings to fall 5% to 10% sequentially from the second quarter.
- CFO Brad Delco said driver recruiting and onboarding costs alone will add about $25 million versus the second quarter.
- J.B. Hunt shares dropped 13% to $236.73 on Wednesday.
- Diesel prices hit $6.29 this week, up 68% from a year earlier, adding a roughly $10 million cost headwind.
- Delco linked the driver shortage partly to federal limits on immigrant eligibility for commercial driving.
- Delco called the added driver spending a sign the company is investing in growth, not just absorbing costs.
BUSINESS, MARKETS & FINANCE
By Kelly Cloonan
Amazon said Wednesday it is lifting its starting hourly wage to $20 for full-time employees in its core U.S. operations roles, a $1 raise timed just ahead of its holiday hiring surge. The higher floor applies to front-line workers who sort, pack and transport orders, and comes alongside new benefits including grocery discounts and access to a credit union offering low-cost banking. Amazon said average pay for core operations employees now reaches nearly $24 an hour, with total average compensation above $32 an hour once benefits are included, and that its minimum has risen more than 17% over three years. Starting Oct. 1, workers get 10% off eligible groceries and other essentials online and 20% off in-store at Whole Foods; banking access through First Tech Federal Credit Union will roll out starting in late 2026.
Why It Matters: Warehouse and delivery workers get a concrete wage floor and new banking benefits right as Amazon competes for hundreds of thousands of seasonal holiday hires.
- Amazon is raising its U.S. minimum starting wage for full-time core operations staff by $1 to $20 an hour.
- The increase applies to front-line workers handling sorting, packing and transporting.
- Average pay for core operations employees is now nearly $24 an hour, with total compensation above $32 including benefits.
- Amazon says its minimum starting pay has risen more than 17% over the past three years.
- Starting Oct. 1, employees get 10% off eligible groceries online and 20% off in-store at Whole Foods.
- Amazon is rolling out membership in First Tech Federal Credit Union, with $0 overdraft fees and no minimums.
- Banking access begins rolling out in late 2026 and becomes broadly available in 2027.
- Last year Amazon planned to hire 250,000 workers for the holiday season.
PRINT ONLY B5 · BUSINESS, MARKETS & FINANCE
Dutch Investor to Acquire Edtech Company Watermark
By Maria Armental
Dutch buyout firm Main Capital Partners agreed to acquire TCV-backed education-technology platform Watermark Insights, its largest U.S. deal since opening an American office in 2023. A person familiar with the matter said the combined enterprise value of Watermark and U.K.-based Tribal Group, which Main Capital agreed to buy last week for about $256 million, approaches $600 million including debt. Main Capital partner Daan Visscher said the deals reflect confidence that higher-education institutions facing tight budgets and complex compliance needs will keep paying for administrative software. Austin-based Watermark, formed in 2018 from a merger including Taskstream and Tk20, serves about 1,500 institutions including Princeton, Purdue and Seton Hall. Advisers say edtech deals are rebounding as buyers bet the sector's compliance-heavy, recurring-revenue software is more insulated from AI disruption than other corners of the software market.
Why It Matters: Buyout firms betting on compliance software as AI-resistant shows where private equity sees safe recurring revenue, a signal for software investors and the roughly 1,500 colleges that rely on Watermark's systems.
- Main Capital Partners agreed to acquire Watermark Insights from TCV
- It is Main Capital's largest U.S. deal since opening an office here in 2023
- Combined value of Watermark and U.K.-based Tribal Group approaches $600 million including debt
- Main Capital agreed to buy Tribal Group separately last week for about $256 million
- Partner Daan Visscher co-heads Main Capital's North America operations
- Watermark was formed in 2018 through a merger including Taskstream and Tk20
- Watermark has more than 300 employees and serves about 1,500 institutions
- Clients include Princeton, Purdue and Seton Hall universities
BUSINESS, MARKETS & FINANCE
By Anthony Harrup
U.S. commercial crude-oil inventories fell for a third straight week, the Energy Information Administration reported, with holdings slipping by 640,000 barrels to reach 423.4 million barrels for the seven days that concluded Sept. 11. The decline was smaller than the 1.4 million-barrel drop analysts had expected in a Wall Street Journal survey, and stocks stayed 1% above the five-year seasonal average. Strategic Petroleum Reserve holdings fell 403,000 barrels to 285 million barrels, while Cushing, Okla. stocks dropped 342,000 barrels. Refinery utilization slipped to 96.8% of capacity from 97.8% the prior week even as crude production held near 13.9 million barrels a day and gasoline inventories rose 794,000 barrels.
Why It Matters: Weekly EIA inventory swings move gasoline and diesel prices at the pump, so a smaller-than-expected draw alongside falling refinery runs matters directly to drivers, refiners and energy traders positioning for the next report.
- Commercial crude stocks dropped 640,000 barrels, reaching 423.4 million for the week that ended Sept. 11
- The draw was smaller than the 1.4 million-barrel drop analysts had forecast
- Crude stocks remained 1% above the five-year seasonal average
- Strategic Petroleum Reserve stocks fell 403,000 barrels to 285 million barrels
- Cushing, Okla. delivery-hub stocks dropped 342,000 barrels
- U.S. crude production held roughly steady at 13.9 million barrels a day
- Refinery utilization fell to 96.8% of capacity from 97.8% a week earlier
- Gasoline inventories increased 794,000 barrels to 207.7 million barrels
HEARD ON THE STREET
By David Wainer
Rare-disease drugmakers, battered earlier in the Trump administration by FDA skepticism toward small-trial evidence, are drawing investors back in as acting Commissioner Kyle Diamantas's agency reverses several tough calls. Replimune's melanoma treatment won approval on its third try, and its shares along with uniQure's have surged as the FDA softened its posture. UniQure, developing a one-time gene therapy for Huntington's disease, saw its stock quadruple then crater after the FDA initially rejected its historical-database trial comparison, before the agency reversed course in June and let the company file for approval. Analyst Joseph Thome of TD Cowen said four-year trial data due by month's end will be scrutinized alongside the three-year results the approval decision rests on. The piece argues the trade is betting the FDA will keep letting patients take on risk before all the clinical evidence is in, not that the therapies themselves are proven.
Why It Matters: A friendlier FDA revives a stock trade in unproven rare-disease therapies, meaning investors and patients alike are betting on regulatory tolerance for risk rather than settled clinical proof of benefit.
- Rare-disease drugmaker shares plunged earlier under FDA skepticism of small-trial evidence
- Acting FDA Commissioner Kyle Diamantas's agency has reversed several prior rejections
- Replimune won approval for its melanoma treatment on a third attempt
- UniQure's Huntington's gene-therapy stock quadrupled, then crashed after an FDA reversal
- The FDA reopened the door to uniQure's filing in June; it filed this month
- Four-year trial data on uniQure's therapy is expected by month's end
- Analyst Joseph Thome of TD Cowen says approval odds are "skewing positive"
- Regenxbio's stock swung on a reversal and then a clinical hold this year
PRINT ONLY B10 · BUSINESS, MARKETS & FINANCE
Stock Spotlight
A roundup of Wednesday's notable stock moves: Coinbase and Strategy fell after the Senate failed to pass the Clarity Act crypto bill, while Intel gained 4% as AI-linked shares began recovering from earlier losses. Reliance Worldwide jumped after Brookfield Asset Management agreed to acquire the Australian plumbing-supplies maker in an all-cash deal, and Reckitt Benckiser slipped slightly despite doubling down on U.S. manufacturing. Frasers Group fell after Hugo Boss named the Frasers CEO as its next supervisory-board chairman, and J.B. Hunt Transport dropped 13% after its CFO warned of a third-quarter earnings decline from higher driver, fuel and medical costs. Papa John's shares also slid after its CEO acknowledged the pizza chain's turnaround is taking longer than hoped. The item closes with a list of Thursday's scheduled central-bank decisions and economic data releases.
Why It Matters: This grab-bag of same-day stock reactions gives investors a quick read on which earnings warnings, deals and policy failures are moving individual names before Thursday's central-bank decisions and data land.
- Coinbase closed down 4.4% and Strategy down 3.8% after the Senate failed to pass the Clarity Act
- Intel rose 4% as AI-linked stocks began recovering from earlier-week losses
- Reliance Worldwide jumped 3.5% on Brookfield's all-cash acquisition agreement
- Reckitt Benckiser shares slipped 0.2% despite a U.S. manufacturing push
- Frasers Group fell 2.6% after its CEO was named Hugo Boss's next chairman
- J.B. Hunt Transport dropped 13% on a warned third-quarter earnings decline
- Papa John's shares closed down 2.6% as its CEO cited a slower turnaround
- Thursday's calendar includes Bank of England and Bank of Japan rate decisions